A number of new specific antibodies, including the anti-CD22 [121], anti-CD40 [122], anti-CD19 [123], anti-CD19/CD3 [124], and anti-CD37 antibodies [125], are currently used for alternative antibody-based therapy in lymphomas. This evidence concerns the gene CD22 and lymphoma.